

Issued: 18 September 2025

Viral Vector Manufacturing Facility (VVMF) at the Cell & Gene Meeting on the Mesa, 2025

Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at the **Cell & Gene Meeting on the Mesa 2025**, October 6-8 2025, at the Arizona Biltmore Hotel, Phoenix, AZ, USA.

VVMF Head of Business Development and Partnerships, Anita van der Meer, will be available to discuss VVMF's expertise in process development, viral vector manufacturing and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.



VVMF's **Anita van der Meer** shared, "The Meeting on the Mesa is an opportunity to connect and build new relationships within the global Cell & Gene therapy sector. We are excited to showcase VVMF's advanced capabilities in lentiviral (rLV) and adeno-associated viral (rAAV) vector process development and manufacturing".

Committed to supporting biotech and pharmaceutical companies, VVMF delivers high-quality viral vector solutions tailored to their research, clinical, and commercial needs. Backed by leading scientific and clinical expertise, VVMF provides a strategic advantage- further strengthened by Australia's 43.5% R&D tax incentive for eligible companies.

Schedule a meeting via the meeting's one-on-one partnering platform or contact us at info@vvmf.com.au to explore how VVMF can be your trusted partner in advancing cell and gene therapies.

Unlocking the future of medicine – with strong connections built at the Cell & Gene Meeting on the Mesa.

About VVMF – Unlocking the Future of Medicine

Viral Vector Manufacturing Facility (VVMF) is an Australian Contract Development Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of recombinant lentiviral (rLV) and recombinant adeno-associated viral (rAAV) viral vectors for advanced therapeutic applications. Located in Sydney's Westmead Health and Innovation precinct, VVMF partners with researchers, clinicians and bio-pharma companies to accelerate the path to market for cell and gene therapies to local patients. Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.